Opko Health Inc. (NASDAQ:OPK) saw a significant increase in short interest in the month of March. As of March 29th, there was short interest totalling 84,990,147 shares, an increase of 4.6% from the March 15th total of 81,261,939 shares. Based on an average daily trading volume, of 4,704,126 shares, the short-interest ratio is presently 18.1 days. Approximately 23.7% of the shares of the company are sold short.
In related news, CEO Phillip Md Et Al Frost bought 80,000 shares of the company’s stock in a transaction dated Monday, April 22nd. The shares were acquired at an average price of $2.32 per share, with a total value of $185,600.00. Following the completion of the acquisition, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $7,119,966.32. The transaction was disclosed in a document filed with the SEC, which is available through this link. In the last ninety days, insiders have acquired 868,000 shares of company stock worth $2,138,580. 42.74% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently bought and sold shares of the business. Norges Bank purchased a new stake in shares of Opko Health in the fourth quarter valued at $9,207,000. Dimensional Fund Advisors LP increased its stake in Opko Health by 25.3% during the third quarter. Dimensional Fund Advisors LP now owns 4,440,784 shares of the biotechnology company’s stock worth $15,363,000 after acquiring an additional 897,406 shares during the last quarter. FMR LLC acquired a new stake in Opko Health during the third quarter worth about $2,362,000. Vanguard Group Inc increased its stake in Opko Health by 2.1% during the third quarter. Vanguard Group Inc now owns 29,660,750 shares of the biotechnology company’s stock worth $102,626,000 after acquiring an additional 614,442 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Opko Health by 2.1% during the third quarter. Vanguard Group Inc. now owns 29,660,750 shares of the biotechnology company’s stock worth $102,626,000 after acquiring an additional 614,442 shares during the last quarter. Institutional investors own 22.69% of the company’s stock.
Opko Health (NASDAQ:OPK) last posted its earnings results on Wednesday, February 27th. The biotechnology company reported ($0.08) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.01. The company had revenue of $221.90 million for the quarter, compared to the consensus estimate of $242.05 million. Opko Health had a negative return on equity of 7.69% and a negative net margin of 15.46%. On average, analysts predict that Opko Health will post -0.2 EPS for the current fiscal year.
A number of research analysts have recently issued reports on OPK shares. Zacks Investment Research lowered Opko Health from a “hold” rating to a “sell” rating in a report on Friday, March 8th. ValuEngine lowered Opko Health from a “hold” rating to a “sell” rating in a report on Wednesday. Finally, Barrington Research reaffirmed a “buy” rating and set a $5.00 price objective on shares of Opko Health in a report on Thursday, February 28th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Opko Health presently has a consensus rating of “Buy” and a consensus price target of $9.25.
TRADEMARK VIOLATION WARNING: This report was posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/05/04/opko-health-inc-opk-short-interest-update-2.html.
Opko Health Company Profile
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.
See Also: What are the FAANG Stocks?
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.